IBD malignancy with Hannah Gordon

About this episode

The episode discusses the balance between effective treatment of inflammatory bowel disease and the associated cancer risks.

In this episode, Pradeep Mundre speaks with Hannah Gordon about one of the most challenging areas in inflammatory bowel disease management: balancing effective treatment with cancer risk. As therapeutic options expand, clinicians increasingly face complex scenarios involving patients with prior malignancy in remission or those undergoing active cancer treatment. The discussion examines how cancer risk relates both to IBD itself and to immunosuppressive or biologic therapies. The episode highlights limitations in current evidence, differences across drug classes, and the importance of individualised decision-making. Emphasis is placed on multidisciplinary collaboration, patient communication, and navigating uncertainty in real-world clinical practice.

People in this episode

Host: Pradeep Mundre

Guest: Hannah Gordon

Topics covered

• inflammatory bowel disease
• cancer risk
• immunosuppressive therapies
• biologic therapies
• multidisciplinary collaboration
• patient communication

Keywords

• IBD
• malignancy
• treatment
• cancer risk
• immunosuppression
• biologics
• clinical practice

Mentioned in this episode

Organizations: UEG United European Gastroenterology

More episodes of UEG Podcast

• MASLD with Sven Francque - Part 2 · June 2, 2026 · 28 min
• MASLD with Sven Francque - Part 1 · May 26, 2026 · 25 min
• UEG Online Courses x UEG Podcast: Consequences of proctology surgery (LARS) · May 12, 2026 · 20 min
• EoE with Alex Straumann - Part 2 · April 28, 2026 · 16 min
• EoE with Alex Straumann - Part 1 · April 21, 2026 · 23 min
• Nutrition in coeliac disease for a clinician with Cristian Costas · March 17, 2026 · 40 min